PharmAthene to add antibody assets in Theraclone merger

Anthrax vaccine developer PharmAthene is to merge with antibody-focused biotech Theraclone Sciences. PharmAthene said the combined company will have four clinical-stage products, giving it the diversified portfolio desired by management. Article

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.